Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care
- PMID: 20391473
- PMCID: PMC3018780
- DOI: 10.1002/acr.20088
Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care
Comment on
-
Impact of the Medicare Modernization Act of 2003 on utilization and spending for medicare part B-covered biologics in rheumatoid arthritis.Arthritis Care Res (Hoboken). 2010 Mar;62(3):354-61. doi: 10.1002/acr.20010. Arthritis Care Res (Hoboken). 2010. PMID: 20391481 Free PMC article.
References
-
- Safran DG, Neuman P, Schoen C, Kitchman MS, Wilson IB, Cooper B, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. URL: http://content.healthaffairs.org/cgi/content/full/hlthaff.w5.152/DC1. - PubMed
-
- Neuman P, Kitchman Strollo M, Guterman S, Rogers WH, Li A, Rodday AM, et al. Medicare prescription drug benefits progress report: findings from a 2006 national survey of seniors. Health Affairs. 2007;26:w630–w643. - PubMed
-
- Iglehart JE. Medicare and drug pricing. N Engl J Med. 2003;348:1590–1597. - PubMed
-
- US General Accounting Office. Medicare: payments for covered outpatient drugs exceed providers' cost. Washington (DC): US General Accounting Office; 2001.
-
- US District Court of Massachusetts. Pharmaceutical industry average wholesale price litigation: findings of fact and conclusions of law. 2007. URL: http://jimedwardsnrx.files.wordpress.com/2009/06/download-abbotts-motion... Findings of fact and conclusions of law.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
